Dentsply Sirona Earnings Fall To $0.29 A Share Despite $39 Million Accounting Benefit
Dental sales weakened across all three businesses, while Wellspect posted record quarterly sales and free cash flow fell to zero.
Dentsply Sirona, which makes dental equipment, implants, clear aligners and consumables, reported third-quarter adjusted earnings of $0.29 a share Thursday, down from $0.42 a year earlier despite a $39 million inventory-accounting benefit. Sales fell to $836 million from $904 million, down 7.6% as reported and 7.0% excluding currency changes, according to results furnished with its SEC filing.
An Earnings Lift That Won’t Repeat
The $39 million benefit came from changing the estimate used to remove unrealized profit from inventory. The revision captured a cumulative effect, reduced the reported net loss and added approximately $30 million to adjusted net income. The company said it does not expect equivalent benefits in future periods.
Even with that help, adjusted net income was $59 million, versus $84 million a year earlier. Adjusted earnings per share declined 29.4%. Adjusted earnings before interest, taxes, depreciation and amortization fell 13.3% to $146 million, and the margin on that measure slipped to 17.3% from 18.4%.
Under standard accounting, the loss attributable to shareholders was $2 million, or $0.01 a share, compared with $427 million, or $2.14 a share, a year earlier. Goodwill and intangible-asset impairment charges were $3 million, versus $262 million in the prior-year quarter. Gross margin rose to 52.9% from 48.8%; the adjusted gross margin was 54.5%, versus 52.6%.
Wellspect Grows, Dental Businesses Shrink
Wellspect Healthcare delivered record quarterly sales of $92 million, up from $83 million. Growth was 10.1% as reported and 11.0% excluding currency movements. The company also launched the Surity Urinary Management System, completing its U.S. Surity portfolio.
The dental businesses moved the other way:
- Connected Technology Solutions generated $230 million, versus $259 million, down 11.0% as reported and 10.1% excluding currency changes.
- Essential Dental Solutions generated $343 million, versus $357 million, down 4.0% as reported and 3.6% excluding currency changes.
- Orthodontic and Implant Solutions generated $171 million, versus $205 million, down 16.6% as reported and 16.2% excluding currency changes.
Dentsply Sirona serves dentists and dental laboratories with products ranging from imaging systems and intraoral scanners to implants and clear aligners. Wellspect supplies continence-care products for urological and bowel management. About two-thirds of the company’s dental consumable, technology and equipment products reach customers through third-party distributors.
Dan Scavilla, president and CEO of Dentsply Sirona, pointed to progress in implants and endodontics and an expanded U.S. dealer network. Describing the company’s return-to-growth plan, he said, “our focus is now on execution,” with sales-force, clinical-education and innovation efforts central to that work.
Zero Free Cash Flow, Continued Buybacks
Third-quarter free cash flow—cash left after capital spending—was zero, versus $40 million a year earlier. Operating cash flow fell to $32 million from $79 million, primarily because of unfavorable working-capital changes, while capital spending was $32 million.
The company nevertheless bought back 1.2 million shares for approximately $13 million during the quarter. Repurchases totaled $25 million for the first nine months of 2026. Cash and equivalents stood at $195 million on September 30, compared with $326 million at the end of 2025.
Dentsply Sirona’s updated full-year outlook calls for approximately $3.5 billion in sales and adjusted earnings of $1.20 to $1.30 a share, excluding a $0.17 one-time tariff-refund benefit.
Sources
- 8-K Filing — DENTSPLY SIRONA Inc. (XRAY) — SEC EDGAR
- Exhibit dentsply8kq32026ex991.htm — DENTSPLY SIRONA Inc. 8-K exhibit — SEC EDGAR
- Dentsply Sirona Q3 2026 Earnings Call Transcript — benzinga.com
- Dentsply Sirona Reports Third Quarter 2026 Results — globenewswire.com